SWAV Overview

New Board Appointment: Bruker Corporation has appointed Laura Francis as an independent director, effective February 18, 2025, and she is expected to join the Audit Committee as a financial expert after the annual shareholder meeting in May 2025.

Background of Laura Francis: Ms. Francis is currently the CEO of SI-BONE, Inc., with extensive experience in executive roles across various life science companies, including previous positions at Bruker Corporation and McKinsey & Company.

Johnson & Johnson's Financial Performance: J&J reported fourth-quarter sales of $22.52 billion, exceeding expectations, with strong growth in cancer treatments, particularly Darzalex, which generated over $3 billion in sales. The company anticipates 2025 sales between $90.9 billion and $91.7 billion.

Acquisitions and Market Impact: Following a $14.6 billion acquisition of Intra-Cellular to enhance its psychiatric drug portfolio, J&J continues to expand its drug and device businesses, despite a decline in sales for its psoriasis treatment Stelara due to the introduction of biosimilars.

J&J Acquires Intra-Cellular Therapies: Johnson & Johnson is set to acquire Intra-Cellular Therapies for $14.6 billion, enhancing its portfolio in neurological treatments and aiming for accelerated growth following the spin-off of its consumer health unit.

Market Reactions and Concerns: The acquisition includes a premium offer for Intra-Cellular's shares, with analysts optimistic about the sales potential of its drug Caplyta; however, concerns regarding potential antitrust scrutiny have been raised due to overlapping products.

Healthcare Market Outlook: Executives and investors anticipate increased initial public offerings (IPOs) and mergers and acquisitions (M&A) in the healthcare sector by 2025, with geopolitical risks now seen as the primary concern over funding challenges.

Confidence in Growth: A significant majority of survey respondents expect a rise in healthcare IPOs and M&A activity, particularly in North America, while weight loss drugs are projected to have a lasting impact on the market.